Enhabit (EHAB) Competitors $9.02 -0.24 (-2.58%) Closing price 03:58 PM EasternExtended Trading$9.23 +0.21 (+2.33%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends EHAB vs. PGNY, AGL, ADUS, TDOC, NHC, AHCO, VRDN, CDNA, AVAH, and GRALShould you be buying Enhabit stock or one of its competitors? The main competitors of Enhabit include Progyny (PGNY), agilon health (AGL), Addus HomeCare (ADUS), Teladoc Health (TDOC), National HealthCare (NHC), AdaptHealth (AHCO), Viridian Therapeutics (VRDN), CareDx (CDNA), Aveanna Healthcare (AVAH), and Grail (GRAL). These companies are all part of the "healthcare" industry. Enhabit vs. Progyny agilon health Addus HomeCare Teladoc Health National HealthCare AdaptHealth Viridian Therapeutics CareDx Aveanna Healthcare Grail Enhabit (NYSE:EHAB) and Progyny (NASDAQ:PGNY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership. Which has preferable earnings & valuation, EHAB or PGNY? Progyny has higher revenue and earnings than Enhabit. Enhabit is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnhabit$1.03B0.44-$80.50M-$3.11-2.90Progyny$1.17B1.60$62.04M$0.5738.35 Do analysts recommend EHAB or PGNY? Enhabit currently has a consensus price target of $8.50, suggesting a potential downside of 5.78%. Progyny has a consensus price target of $24.82, suggesting a potential upside of 13.53%. Given Progyny's stronger consensus rating and higher possible upside, analysts plainly believe Progyny is more favorable than Enhabit.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enhabit 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Progyny 0 Sell rating(s) 9 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.31 Is EHAB or PGNY more profitable? Progyny has a net margin of 5.03% compared to Enhabit's net margin of -11.24%. Progyny's return on equity of 11.36% beat Enhabit's return on equity.Company Net Margins Return on Equity Return on Assets Enhabit-11.24% 1.67% 0.80% Progyny 5.03%11.36%7.87% Does the MarketBeat Community favor EHAB or PGNY? Progyny received 96 more outperform votes than Enhabit when rated by MarketBeat users. Likewise, 70.63% of users gave Progyny an outperform vote while only 17.24% of users gave Enhabit an outperform vote. CompanyUnderperformOutperformEnhabitOutperform Votes517.24%Underperform Votes2482.76% ProgynyOutperform Votes10170.63% Underperform Votes4229.37% Does the media refer more to EHAB or PGNY? In the previous week, Progyny had 8 more articles in the media than Enhabit. MarketBeat recorded 8 mentions for Progyny and 0 mentions for Enhabit. Progyny's average media sentiment score of 1.21 beat Enhabit's score of 1.00 indicating that Progyny is being referred to more favorably in the news media. Company Overall Sentiment Enhabit Positive Progyny Positive Which has more risk and volatility, EHAB or PGNY? Enhabit has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500. Comparatively, Progyny has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Do insiders & institutionals have more ownership in EHAB or PGNY? 94.9% of Progyny shares are owned by institutional investors. 1.9% of Enhabit shares are owned by company insiders. Comparatively, 12.3% of Progyny shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryProgyny beats Enhabit on 17 of the 18 factors compared between the two stocks. Remove Ads Get Enhabit News Delivered to You Automatically Sign up to receive the latest news and ratings for EHAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EHAB vs. The Competition Export to ExcelMetricEnhabitHome health care services IndustryMedical SectorNYSE ExchangeMarket Cap$455.38M$3.13B$5.70B$19.53BDividend YieldN/A0.33%4.41%3.80%P/E Ratio-3.8929.0824.1533.44Price / Sales0.441.13394.5828.12Price / Cash3.2517.2938.1617.54Price / Book0.653.427.104.56Net Income-$80.50M-$57.02M$3.19B$1.02B7 Day Performance5.20%2.42%1.79%0.95%1 Month Performance10.89%5.97%2.32%-3.92%1 Year Performance-20.94%20.13%14.79%5.10% Enhabit Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EHABEnhabit1.2173 of 5 stars$9.02-2.6%$8.50-5.8%-19.2%$455.38M$1.03B-3.8910,800PGNYProgyny2.507 of 5 stars$20.91+2.7%$24.82+18.7%-40.7%$1.79B$1.17B36.05310Positive NewsAGLagilon health1.0048 of 5 stars$4.19+3.6%$3.95-5.7%-25.7%$1.73B$6.06B-4.46650Analyst ForecastOptions VolumeNews CoverageADUSAddus HomeCare4.9254 of 5 stars$93.39+3.4%$132.78+42.2%-10.2%$1.70B$1.15B21.3733,200TDOCTeladoc Health3.3414 of 5 stars$8.86+2.8%$11.26+27.1%-47.0%$1.54B$2.57B-1.545,100NHCNational HealthCareN/A$92.82-0.9%N/AN/A$1.43B$1.30B11.6312,400AHCOAdaptHealth3.5929 of 5 stars$9.74+1.5%$13.80+41.7%-8.3%$1.31B$3.26B-5.9010,900Positive NewsVRDNViridian Therapeutics1.5671 of 5 stars$16.04+0.8%$35.70+122.6%-15.4%$1.31B$302,000.00-3.7250Positive NewsCDNACareDx3.4419 of 5 stars$19.27+2.0%$31.83+65.2%+88.6%$1.07B$333.79M-7.14740Positive NewsAVAHAveanna Healthcare0.5804 of 5 stars$5.51+6.2%$4.94-10.4%+123.8%$1.06B$2.02B-16.2133,500Insider TradeHigh Trading VolumeGRALGrail0.8996 of 5 stars$29.13-2.1%$16.00-45.1%N/A$987.36M$125.60M0.001,360Analyst ForecastPositive News Remove Ads Related Companies and Tools Related Companies PGNY Competitors AGL Competitors ADUS Competitors TDOC Competitors NHC Competitors AHCO Competitors VRDN Competitors CDNA Competitors AVAH Competitors GRAL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:EHAB) was last updated on 3/21/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enhabit, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enhabit With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EHAB Stock Alerts